find epidemiolog studi relationship fruit veget consumpt renal cell carcinoma rcc risk inconclus studi associ fruit veget risk rcc popul-base prospect cohort studi swedish women collect dietari inform 000 women ag 40-76 year food-frequenc questionnair 13.4 year follow-up 122 women develop rcc cox proport hazard model us estim rel risk confid interv women consum serv fruit veget daili rel risk 0.59 0.26-1.34 comparison consum onc daili fruit veget examin separ consum serv per month fruit veget multivari rel risk 0.59 0.27-1.25 0.60 0.31-1.17 respect compar consum serv per month group fruit strongest invers associ observ banana 0.07 wald test risk rcc increas monoton increas intak frequenc fruit juic p-valu trend 0.10 group veget strongest invers associ observ root veget 0.03 wald test risk rcc decreas increas consumpt frequenc white cabbag trend 0.07 frequent consumpt salad veget onc per dai decreas risk 0.60 0.30-1.22 comparison consumpt result suggest high consumpt fruit veget associ reduc risk rcc
renal cell carcinoma rcc show variou clinic behavior current surgic modal effect therapi cancer discern genom background affect clinic characterist metastasi analyz gene express profil rcc dna microarrai us cell line origin primari metastat lesion rna extract ten skrc rcc cell line gene express profil perform us cdna microarrai 000 human cdna clone compar gene express profil skrc cell line normal renal proxim tubular cell line among skrc cell line show differ characterist cluster select gene reveal similar profil pattern skrc-17 skrc-29 cell deriv metastat rcc lesion anoth cell line metastat lesion skrc-52 uniqu spindl-shape morpholog differ pattern express profil cell line found sever gene up-regul cell line metastat lesion transgelin reportedli involv cell prolifer migrat up-regul skrc-52 uniqu profil pattern gene express clearli correl cell morpholog metastat potenti profil contribut identifi gene involv clinic characterist rcc
search medlin databas asco 2003 confer proceed conduct identifi clinic trial current underwai us singl-agent therapi renal cell carcinoma rcc combin trial identifi us asco 2003 confer proceed fourteen singl-agent therapi emploi differ mechan action identifi publish literatur imatinib mesyl gleevec bevacizumab avastin thalidomid thalomid gefitinib zd1839 iressa cetuximab imc-c225 erbitux bortezomib ps-341 velcad hsppc-96 oncophag bai 59-8862 abt-510 g250 cci-779 su5416 ptk/zk abx-egf six distinct field clinic research emerg monoclon antibodi small molecul vaccin second-gener taxan nonapeptid immunomodul five combin regimen primarili biolog respons modifi interleukin-2 interferon-alpha chemotherapi- thalidomid-base identifi therapi demonstr accept toxic profil clinic benefit assess base studi's report criteria antitumor respons regress stabil rang past sever year signific advanc underli biolog mechan rcc particularli role tumor angiogenesi permit design molecularli target therapeut base preliminari limit studi combin therapi offer greatest clinic benefit manag malign addit basic research still warrant
background diffus physic process base random movement water molecul known brownian movement diffus-weight imag dwi magnet reson techniqu provid inform biophys properti tissu cell organ densiti microstructur microcircul materi method twenti healthi volunt patient renal tumor enrol studi dwi obtain befor contrast media inject singl-shot epi invers recoveri sequenc tumor cellular resect lesion evalu result mean appar diffus coeffici adc valu renal tumor significantli lower mean adc valu normal renal parenchyma seri mean adc valu renal tumor significantli correl tumor cellular correl histolog architectur conclus preliminari result indic util dwi acquisit tissu character data renal mass us minim acquisit time sec
obes associ increas risk certain cancer includ renal cell carcinoma possibl mediat risk insulin-like growth factor-1 igf-1 author evalu prognost inform igf-1 igfbp-3 leptin prealbumin sera sampl diagnosi 256 consecut patient renal cell carcinoma insulin-like growth factor-1 leptin posit correl bodi mass index bmi insulin-like growth factor-1 igfbp-3 correl tumour stage grade leptin prealbumin both invers relat tumour stage grade surviv analys patient level median igf-1 leptin prealbumin prognosi favour compar lower level 0.017 0.024 p&lt 0.0001 respect multivari analysi tumour stage serum igf-1 level independ prognost factor result indic serum igf-1 diagnosi relat prognosi renal cell carcinoma
background renal cell carcinoma rcc famili carcinoma aris renal tubular epithelium through differ genet lesion most common characterst rcc hypervascular tendenc metastas wide befor give rise symptom sign poor prognosi report matrix metallopropteinas mmp famili endopeptidas implic tissu remodel cancer invas aim present studi investig express mmp-2 rcc correl express clinicopatholog prognost paramet materi method fifti case primari rcc compris materi studi formalin-fix paraffin-embed tissu stain mmp-2 immunostain us improv streptavidin-biotin amplifi system intens stain percentag posit cell assess result mmp-2 express diffus brown cytoplasm stain posit cell non-tumor renal tissu show neg stain wherea tumor cell fibroblast vascular endotheli cell show immunoreact posit case 43/50 rcc case studi posit mmp-2 posit correl observ mmp-2 express tumor size histolog type capsular &amp vascular invas high level cellular prolifer conclus seem mmp-2 involv tumor expans phenomena associ tumor progress invas microvasculatur distant metastasi rcc
